Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

21.85
-0.2091-0.95%
Post-market: 21.850.00000.00%19:30 EDT
Volume:21.35K
Turnover:467.19K
Market Cap:49.49M
PE:- -
High:22.17
Open:22.03
Low:21.76
Close:22.06
52wk High:27.02
52wk Low:15.63
Shares:2.26M
Float Shares:2.26M
Volume Ratio:0.52
T/O Rate:0.94%
Dividend:1.68
Dividend Rate:7.70%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Israel's Entera Bio Q2 Net Loss Widens

Reuters
·
Aug 08

Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)

TIPRANKS
·
Aug 08

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans

GlobeNewswire
·
Aug 08

Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE)

TIPRANKS
·
Aug 08

NRx Pharmaceuticals Shares Rise After FDA Finishes Ketamine Review

Dow Jones
·
Aug 08

Analysts Are Bullish on Top Healthcare Stocks: Relmada Therapeutics (RLMD), Delcath Systems (DCTH)

TIPRANKS
·
Aug 07

FDA completes review of NRx Pharmaceuticals preservative-free ketamine ANDA

TIPRANKS
·
Aug 07

FDA Flags Packaging Certification as Sole Major Deficiency for NRx Preservative-Free Ketamine ANDA Approval

Reuters
·
Aug 07

NRX Pharmaceuticals - FDA Finds no Major Deficiencies in Ketamine Anda First-Cycle Review

THOMSON REUTERS
·
Aug 07

NRX Pharmaceuticals - no New Clinical or Safety Data Required for Ketamine Anda Approval

THOMSON REUTERS
·
Aug 07

NRX Pharmaceuticals - FDA to Review Certification in Shortest Possible Cycle After Aug 6, 2026 Meeting

THOMSON REUTERS
·
Aug 07

FDA Completes First-Cycle Review of Preservative-Free Ketamine Anda with no Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval

THOMSON REUTERS
·
Aug 07

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Dow Jones
·
Aug 07

Wingara Ag sets AGM to approve capital raising tools and board re-elections

TIPRANKS
·
Aug 07

Relmada Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Relmada Publishes Investor Presentation Highlighting NDV-01 Program for Non-Muscle Invasive Bladder Cancer

Reuters
·
Aug 07

Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 07

Relmada Therapeutics Q2 EPS USD -0.11

Reuters
·
Aug 07

Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 07

The Race to Come up with the Next Big Sleep Drug

Dow Jones
·
Aug 07